Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Official title: A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Key Details
Gender
All
Age Range
Any - 30 Years
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2022-09-13
Completion Date
2025-12-03
Last Updated
2026-06-26
Healthy Volunteers
No
Conditions
Interventions
Relatlimab
Specified Dose on Specified Days
Nivolumab
Specified Dose on Specified Days
Locations (51)
Local Institution - 0077
Birmingham, Alabama, United States
Local Institution - 0024
Phoenix, Arizona, United States
Local Institution - 0035
Palo Alto, California, United States
Local Institution - 0032
New Haven, Connecticut, United States
Local Institution - 0066
Fort Myers, Florida, United States
Local Institution - 0073
Baltimore, Maryland, United States
Local Institution - 0025
Minneapolis, Minnesota, United States
Local Institution - 0020
Jackson, Mississippi, United States
Local Institution - 0071
Hackensack, New Jersey, United States
Local Institution - 0060
New York, New York, United States
Local Institution - 0059
Valhalla, New York, United States
Local Institution - 0029
Austin, Texas, United States
Local Institution - 0026
San Antonio, Texas, United States
Local Institution - 0037
Randwick, New South Wales, Australia
Royal Childrens Hospital RCH - Queensland Childrens Hospital
South Brisbane, Queensland, Australia
Local Institution - 0042
Nedlands, Western Australia, Australia
CHU dAngers - Pole Pediatrie
Angers, Angers Cedex 9, France
Groupe Hospitalier Pellegrin - Hopital des enfants
Bordeaux, France
Local Institution - 0033
Caen, France
Local Institution - 0067
La Tronche, France
Institut d Hematologie et d Oncologie Pediatriques
Lyon, France
Centre Hospitalier Universitaire de Montpellier CHU Montpellier - Hopital Arnaud de Villeneuve
Montpellier, France
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Armand-Trousseau
Paris, France
Assistance Publique-Hopitaux de Paris AP-HP - Hopital Universitaire Robert-Debre
Paris, France
CHRU de Strasbourg-Hopital de Hautepierre
Strasbourg, France
Fondazione IRCCS Istituto Nazionale Dei Tumori
Milan, Milano, Italy
Local Institution - 0010
Aviano, Italy
Azienda Ospedaliero Universitaria di Bologna
Bologna, Italy
Local Institution - 0040
Florence, Italy
Local Institution - 0070
Milan, Italy
Fondazione MBBM - Clinica Pediatrica
Monza, Italy
Azienda Ospedale Universita Padova
Padova, Italy
Local Institution - 0041
Pavia, Italy
Local Institution - 0002
Roma, Italy
Local Institution - 0004
Turin, Italy
Princess Maxima Center for pediatric oncology
Utrecht, Netherlands
Local Institution - 0069
Esplugues de Llobregat, Barcelona, Spain
Local Institution - 0030
Madrid, Madrid, Spain
Local Institution - 0046
Barcelona, Spain
Local Institution - 0058
Madrid, Spain
Local Institution - 0044
Madrid, Spain
Local Institution - 0055
Madrid, Spain
Local Institution - 0045
Madrid, Spain
Local Institution - 0062
Pamplona, Spain
Local Institution - 0023
Seville, Spain
Local Institution - 0049
Valencia, Spain
Local Institution - 0075
Cambridge, Cambridgeshire, United Kingdom
Local Institution - 0074
Liverpool, England, United Kingdom
Local Institution - 0054
London, Londonderry, United Kingdom
Local Institution - 0068
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Local Institution - 0053
London, United Kingdom